中国药物警戒 ›› 2025, Vol. 22 ›› Issue (4): 460-462.
DOI: 10.19803/j.1672-8629.20240760

• 安全与合理用药 • 上一篇    下一篇

信迪利单抗注射液致晚期长生存肺腺癌患者白癜风1例分析

刘亚岚1,3, 刘燕湘2, 陈鹏3,*   

  1. 1邵阳市中心医院肿瘤内科,湖南 邵阳 422000;
    2邵阳市中心医院临床药学部,湖南 邵阳 422000;
    3天津医科大学肿瘤医院肺部肿瘤内科,国家肿瘤临床医学研究中心,天津 300060
  • 收稿日期:2024-09-30 发布日期:2025-04-17
  • 通讯作者: *陈鹏,男,博士,主任医师,抗癌药物研发与液体基因检测。E-mail: chenpengdoc@sina.com
  • 作者简介:刘亚岚,女,在读博士,主治医师,恶性肿瘤综合诊疗。
  • 基金资助:
    湖南省卫生健康委科研计划项目（202203103104）

One Case of Vitiligo Caused by Sintilimab Injection in a Patient with Advanced Long-Term Survival Lung Adenocarcinoma

LIU Yalan1,3, LIU Yanxiang2, CHEN Peng3,*   

  1. 1Department of Oncology, the Central Hospital of Shaoyang, Shaoyang Hunan 422000, China;
    2Department of Clinical Pharmacology, the Central Hospital of Shaoyang, Shaoyang Hunan 422000, China;
    3Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China
  • Received:2024-09-30 Published:2025-04-17

PDF (PC)

98

摘要： 目的 探讨白癜风的发生与程序性死亡受体 1（PD-1）/程序性死亡配体1（PD-L1）抑制剂治疗临床获益之间的关系，为临床安全用药和不良反应监测提供参考。方法 分析1例肺腺癌患者应用信迪利单抗致白癜风病例，并检索PubMed、Web of Science、中国知网全文数据库中自2000年1月1日至2024年9月1日 PD-1/PD-L1抑制剂引起皮肤白癜风的报道进行讨论。结果 本例患者在使用PD-1抑制剂33个月后发生白癜风。结合患者临床表现和用药时间的相关性，考虑白癜风很可能由信迪利单抗引起。经文献分析，纳入分析的患者共20例，首次使用 PD-1/PD-L1抑制剂至发生白癜风最短时间为免疫治疗第1个月后，最长是第20个月后，15例出现在免疫治疗的3～8个月。结论 临床应用PD-1/PD-L1抑制剂要关注发生白癜风的风险，白癜风的发生可能与免疫治疗预后良好密切相关。

关键词: 信迪利单抗, 白癜风, 肺腺癌, 程序性死亡受体 1, 程序性死亡配体1, 药品不良反应

Abstract: Objective To investigate the relationship between the occurrence of vitiligo and the clinical benefits of programmed cell death-1(PD-1)/ programmed cell death-ligand 1(PD-L1) inhibitors in order to provide a reference for clinical safety and monitoring of Adverse Drug Reactions. Methods One case of vitiligo induced by sintilimab in a patient with pulmonary adenocarcinoma was analyzed. Case reports of vitiligo caused by PD-1/PD-L1 inhibitors collected between January 1, 2000 and September 1, 2024 were retrieved from PubMed, Web of Science and CNKI full-text databases. Descriptive statistical analysis was performed. Results The patient developed vitiligo 33 months after usingPD-1 inhibitors. The correlation between clinical manifestations and the duration of medication suggested that vitiligo was likely to be caused by sintilimab. Based on the literature review, a total of 20 patients were included in the analysis. The earliest onset was one month after immunotherapy with PD-1/PD-L1 inhibitors, and the longest one 20 months later. Fifteen cases occurred within 3 to 8 months of immunotherapy. Conclusion Clinicians who prescribe PD-1/PD-L1 inhibitors should be alert to the risk of vitiligo. The occurrence of vitiligo may be closely related to the good prognosis of immunotherapy.

Key words: Sintilimab, Vitiligo, Adenocarcinoma of Lungs, Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Adverse Drug Reactions

中图分类号: